TOP STORIES

• REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
  April 5, 2022

• ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
  April 5, 2022

• REGULATORY Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
  April 5, 2022

• ORGANIZATION Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
  April 4, 2022

• REGULATORY Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
  April 4, 2022

• BUSINESS COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
  April 1, 2022

• REGULATORY Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
  April 1, 2022

• REGULATORY 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
  March 31, 2022

• BUSINESS Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
  March 30, 2022

• REGULATORY Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
  March 29, 2022

• REGULATORY Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
  March 28, 2022

• ORGANIZATION FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
  March 28, 2022

• REGULATORY Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
  March 25, 2022

• REGULATORY Japan Panel Agrees to Prep for Fourth Shot, but Wants Cautious Approach; Free Booster OK’ed for Ages 12-17
  March 25, 2022

• REGULATORY Enhertu Braced for Price Cuts as Chuikyo OKs CEA Results; Evrysdi Not Subject to Scheme
  March 24, 2022

• REGULATORY Pfizer COVID Booster OK’ed for Ages 12-17, Comirnaty Label Revised
  March 24, 2022

• REGULATORY Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
  March 23, 2022

• REGULATORY AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
  March 23, 2022

• ORGANIZATION Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
  March 22, 2022

• BUSINESS Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
  March 22, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• 77
• 78
• …
• Next ›
• 最終 »